Orchid Pharma Limited (ORCHPHARMA.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-115.8%

-₹133.52

vs ₹843.30 price

Levered DCF

-₹167.87

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

—

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	119.12×	39.84×	58.05×	33.77×	-594.17×	-84.33×	-1.22×	2.31×
P/B	1.9×	3.13×	4.58×	2.27×	1.8×	15.05×	0.21×	-0.23×
P/S	3.02×	4.31×	6.53×	2.35×	2.08×	21.83×	0.33×	0.27×
EV / EBITDA	57.3×	28.51×	38.63×	13.1×	22.98×	157.9×	12.15×	16.52×
Gross margin	19.5%	38.5%	16.6%	10.6%	41.5%	46.4%	53.7%	4.1%
Operating margin	0.7%	8.8%	9.5%	4.5%	-6.1%	-11.2%	-14.5%	-12.3%
Net margin	2.5%	10.8%	11.3%	7.0%	-0.3%	-25.9%	-27.1%	11.6%
Current ratio	2.45×	2.83×	3.04×	1.35×	1.65×	3.87×	3.25×	0.3×
Debt / equity	0.28×	0.14×	0.12×	0.48×	0.41×	0.69×	0.74×	-4.59×
Interest coverage	0.43×	5.58×	4.64×	0.9×	-1.01×	-0.97×	-11.25×	-11.01×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	1.6%	7.9%	7.9%	6.7%	-0.3%	-17.8%	-17.1%	-9.9%
Return on invested capital	0.3%	5.6%	5.9%	2.8%	-3.6%	-4.5%	-5.2%	-3.0%
Return on assets	1.1%	5.9%	5.9%	3.8%	-0.2%	-9.4%	-9.0%	2.3%
Free cash flow yield	-11.2%	-3.3%	1.1%	-4.3%	6.7%	0.2%	47.9%	3.4%
Earnings yield	0.8%	2.5%	1.7%	3.0%	-0.2%	-1.2%	-82.0%	43.3%
Enterprise value	₹28B	₹41.2B	₹54.8B	₹18.7B	₹14.3B	₹102.6B	₹6.4B	₹33B
Net debt / EBITDA	7.27×	1.06×	0.93×	2.16×	4.24×	6.72×	9.09×	15.72×
Cash conversion cycle (days)	134	163	108	151	117	175	117	-10